
French Ipsen falls after Epizyme take-over announcement
Even if Ipsen succeeds in halving the losses at Epizyme Inc, this would reduce the group's profit by nine percent by 2024, Credit Suisse analysts...

Andera Partners co-leads $118m Series B of Mineralys thx (USA)
Mineralys plans to use the proceeds to continue to advance MLS-101, a highly selective aldosterone synthase inhibitor. MLS-101 is currently being...

From waste to sugar - demonstration plant opens in Wales
The project’s 11-strong European consortium secured €7m funding from Circular bio-based Europe JU (formerly Bio Based Industries Joint Undertaking)...

Hot of the press: BIOTECH Insight Newsletter
According to the results of the Biotechnology Company Survey 2022 conducted by BIOCOM AG (Berlin), the turnover of the German biotech sector grew...

Study shows advantages of cellular agriculture
Replacing animal-source foods (ASFs) with novel or future foods (NFFs) – such as cultured milk, insect meal or mycoprotein – or plant-based...

Four new autoantigens trigger multiple sclerosis
Despite considerable progress in the treatment of multiplesclerosis (MS), the disease still often leads to permanent neurological disability....

$50m for London CHARM Therapeutics for deep minded folding expertise
London based CHARM Therapeutics rushes into the 3D deep-learning space with a $50M Series A financing co-led by F-Prime Capital and OrbiMed, with...